Robert H. Wiltrout

13.2k citations

183 papers · 10.3k indexed · h-index 59

Impact in

Immunology top 0.2%
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- T-cell and B-cell Immunology
- Immune Response and Inflammation
- Immune cells in cancer
Oncology top 0.5%
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers

Papers in

Immunology 135
- Immune Cell Function and Interaction 86
- Immunotherapy and Immune Responses 62
- T-cell and B-cell Immunology 31
- Immune cells in cancer 20
Oncology 70
- CAR-T cell therapy research 22
- Cancer Immunotherapy and Biomarkers 20
- Cytokine Signaling Pathways and Interactions 11

Co-authors: Timothy Back Howard A. Young Ronald B. Herberman Jon M. Wigginton Jonathan M. Weiss John R. Ortaldo Jeffrey Subleski Kristin L. Komschlies
Journals: The Journal of Immunology (39 papers)JNCI Journal of the National Cancer Institute (9 papers)Cancer Research (8 papers)The Journal of Experimental Medicine (7 papers)Journal of Leukocyte Biology (5 papers)
Partner nations: United States Japan India

In The Last Decade

Robert H. Wiltrout

181 papers receiving 10.0k citations

Peers

Countries citing papers authored by Robert H. Wiltrout

Since Specialization

Citations

This map shows the geographic impact of Robert H. Wiltrout's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert H. Wiltrout with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert H. Wiltrout more than expected).

Fields of papers citing papers by Robert H. Wiltrout

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert H. Wiltrout. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert H. Wiltrout. The network helps show where Robert H. Wiltrout may publish in the future.

Co-authors

The 25 scholars most cited alongside Robert H. Wiltrout, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Robert H. Wiltrout Line = papers co-authored together Robert H. Wiltrout links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	NOS Inhibition Modulates Immune Polarization and Improves Radiation-Induced Tumor Growth Delay Cancer Research ·Lisa A. Ridnour, Robert Y.S. Cheng, Jonathan M. Weiss, Sukhbir Kaur, David R. Soto‐Pantoja, Debashree Basudhar, Julie L. Heinecke, Charles A. Stewart, William DeGraff, Anastasia L. Sowers, Angela Thetford, Aparna H. Kesarwala, David D. Roberts, Howard A. Young, James B. Mitchell, Giorgio Trinchieri, Robert H. Wiltrout, David A. Wink	2015	35
2	Out-of-Sequence Signal 3 Paralyzes Primary CD4+ T-Cell-Dependent Immunity Immunity ·Gail D. Sckisel, Myriam N. Bouchlaka, Arta M. Monjazeb, Marka R. Crittenden, Brendan D. Curti, Danice Wilkins, Kory A. Alderson, Can M. Sungur, Erik Ames, Annie Mirsoian, Abhinav Reddy, Warren S. Alexander, Athena M. Soulika, Bruce R. Blazar, Dan L. Longo, Robert H. Wiltrout, William J. Murphy	2015	88
3	mTOR Kinase Inhibitor AZD8055 Enhances the Immunotherapeutic Activity of an Agonist CD40 Antibody in Cancer Treatment Cancer Research ·Qun Jiang, Jonathan M. Weiss, Timothy Back, Tim Hon Man Chan, John R. Ortaldo, Sylvie M. Guichard, Robert H. Wiltrout	2011	71
4	Coactivation of AKT and β-Catenin in Mice Rapidly Induces Formation of Lipogenic Liver Tumors Cancer Research ·Jimmy K. Stauffer, Anthony J. Scarzello, Jesper B. Andersen, Rachel L. De Kluyver, Timothy Back, Jonathan M. Weiss, Snorri S. Thorgeirsson, Robert H. Wiltrout	2011	68
5	Antigen Presented by Tumors In vivo Determines the Nature of CD8+ T-Cell Cytotoxicity Cancer Research ·Anil Shanker, Alan D. Brooks, Kristen M. Jacobsen, John W. Wine, Robert H. Wiltrout, Hideo Yagita∥, Thomas J. Sayers	2009	38
6	Nitric Oxide Is a Key Component in Inflammation-Accelerated Tumorigenesis Cancer Research ·S. Perwez Hussain, Peijun He, Jeffrey Subleski, Lorne J. Hofseth, Glenwood E. Trivers, Leah E. Mechanic, Anne B. Hofseth, Mark E. Bernard, Jonathan Schwank, Giang Huong Nguyen, Ewy A. Mathé, Draginja Djurickovic, Diana C. Haines, Jonathan M. Weiss, Timothy Back, Eilene Gruys, Victor E. Laubach, Robert H. Wiltrout, Curtis C. Harris	2008	85
7	Compressing drug development timelines in oncology using phase '0' trials Nature reviews. Cancer ·Shivaani Kummar, Robert J. Kinders, Larry Rubinstein, Ralph E. Parchment, Anthony J. Murgo, Jerry M. Collins, Oxana K. Pickeral, Jennifer A. Low, Seth M. Steinberg, Martin Gutierrez, Sherry X. Yang, Lee J. Helman, Robert H. Wiltrout, Joseph E. Tomaszewski, James H. Doroshow	2007	145
8	Constitutive expression of functional CD40 on mouse renal cancer cells: Induction of Fas and Fas-mediated killing by CD40L Cellular Immunology ·J.-K. Lee, Naoko Seki, Thomas J. Sayers, Jeffrey Subleski, E Gruys, William J. Murphy, Robert H. Wiltrout	2005	16
9	Nitric Oxide, a Mediator of Inflammation, Suppresses Tumorigenesis Cancer Research ·S. Perwez Hussain, Glennwood E. Trivers, Lorne J. Hofseth, Peijun He, Irfan Ahmed Shaikh, Leah E. Mechanic, Saira Doja, Weidong Jiang, Jeffrey Subleski, Lynnette Shorts, Diana C. Haines, Victor E. Laubach, Robert H. Wiltrout, Draginja Djurickovic, Curtis C. Harris	2004	108
10	Tumor regression by anti-CD40 and interleukin-2: role of CD40 in hematopoietic cells and organ-specific effects Biology of Blood and Marrow Transplantation ·(unknown), Lynnette Shorts, Jeff Subleski, Bruce R. Blazar, Robert H. Wiltrout, William J. Murphy	2004	5
11	In vivo administration of IL-18 can induce IgE production through Th2 cytokine induction and up-regulation of CD40 ligand (CD154) expression on CD4+ T cells European Journal of Immunology ·Tomoaki Hoshino, Hideo Yagita, John R. Ortaldo, Robert H. Wiltrout, Howard A. Young	2000	148
12	Quantitative analysis of rod-cored vesicles and dense granules of large granular lymphocytes in the liver, spleen, and peripheral blood of rats Cell and Tissue Research ·Kenji Kaneda, Anne M. Pilaro, Thoma J. Sayers, Kunio Nagashima, Matthew A. Gonda, John R. Ortaldo, Robert H. Wiltrout	1994	3
13	Reversal of Drug Resistance in a Human Colon Cancer Xenograft Expressing MDR1 Complementary DNA by In Vivo Administration of MRK-16 Monoclonal Antibody JNCI Journal of the National Cancer Institute ·Jane Pearson, William E. Fogler, K Völker, Noriaki Usui, Saul Goldenberg, E. Gruys, Charles W. Riggs, Kristin L. Komschlies, Robert H. Wiltrout, T. Tsuruo, Ira Pastan, Michael M. Gottesman, DL Longo	1991	66
14	An improved in vitro assay to quantitate chemotaxis of rat peripheral blood large granular lymphocytes (LGL) Journal of Immunological Methods ·Anne M. Pilaro, Thomas J. Sayers, Kathryn McCormick, Craig W. Reynolds, Robert H. Wiltrout	1990	27
15	Flavone-8-acetic acid augments systemic natural killer cell activity and synergizes with IL-2 for treatment of murine renal cancer. The Journal of Immunology ·Robert H. Wiltrout, Michael R. Boyd, Timothy Back, Raoul Salup, Jaffe Arthur, Ronald L. Hornung	1988	55
16	Characterization and functions of natural killer cells Annales de l Institut Pasteur Immunologie ·John R. Ortaldo, Bonnie J. Mathieson, Robert H. Wiltrout	1988	9
17	Increase in liver-associated natural killer activity by polyribonucleotides. PubMed ·T. A. Twilley, Llewellyn H. Mason, James E. Talmadge, Robert H. Wiltrout	1987	10
18	Immunomodulatory effects in mice of polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose. PubMed ·James E. Talmadge, Joanne S. Adams, Hamblin Phillips, Margaret S. Collins, Barbara Lenz, Mark Schneider, E. Schlick, R. Ruffmann, Robert H. Wiltrout, Michael A. Chirigos	1985	42
19	Immunomodulation of natural killer activity by polyribonucleotides. PubMed ·Robert H. Wiltrout, Raoul Salup, T. A. Twilley, James E. Talmadge	1985	22
20	Immunomodulation and antitumor effects of MVE-2 in mice. PubMed ·James E. Talmadge, Annette E. Maluish, Margaret S. Collins, Mark Schneider, Ronald B. Herberman, Robert K. Oldham, Robert H. Wiltrout	1984	15

About Robert H. Wiltrout

Robert H. Wiltrout is a scholar working on Immunology, Oncology, Biotechnology, Hematology and Toxicology, having authored 183 papers that have together received 10.3k indexed citations. Recurring topics across this work include Immune Cell Function and Interaction (86 papers), Immunotherapy and Immune Responses (62 papers), T-cell and B-cell Immunology (31 papers), CAR-T cell therapy research (22 papers), Cancer Immunotherapy and Biomarkers (20 papers), Immune cells in cancer (20 papers), Hematopoietic Stem Cell Transplantation (12 papers) and Cytokine Signaling Pathways and Interactions (11 papers). The work is most often cited by research in Immunology (6.1k citations), Oncology (3.4k citations), Cancer Research (1.1k citations), Hematology (765 citations) and Molecular Biology (3.1k citations). Robert H. Wiltrout has collaborated with scholars based in United States, Japan and India. Frequent co-authors include Timothy Back, Howard A. Young, Ronald B. Herberman, Jon M. Wigginton, Jonathan M. Weiss, John R. Ortaldo, Jeffrey Subleski, Kristin L. Komschlies, Tomoaki Hoshino and James E. Talmadge. Their work appears in journals such as The Journal of Immunology, JNCI Journal of the National Cancer Institute, Cancer Research, The Journal of Experimental Medicine and Journal of Leukocyte Biology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact